EGFR and non-small cell lung carcinoma: Activating EGFR mutations are mainly the exon 19 deletions (Del19) and the L858R point mutation in exon 21, which are known to be the most important predictive factors for sensitivity to EGFR TKIs and are used for selection of EGFR TKIs in NSCLC [5,81].